{
  "id": 6941989,
  "title": "SeaStar Medical at H.C. Wainwright: adult trial looms over small cap",
  "url": "https://urgent.news/2026/09/12/seastar-medical-at-h-c-wainwright-adult-trial-looms-over-small-cap",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-12T14:24:30.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/seastar-medical-at-hc-wainwright-adult-trial-looms-over-small-cap-93CH-4898662"
  },
  "original_language": "en",
  "account": "On 11 September 2026 at the H.C. Wainwright 28th Annual Global Investment Conference, SeaStar Medical CEO Eric Schlorff presented a dual narrative about the company's two product pipelines - a pediatric therapy QUELIMMUNE, already on the market, and an adult acute kidney injury (AKI) program NEUTRALIZE-AKI, still in development. The stock closed at $3.03, down 3.19% from the day before, and further declined to $2.98 in after-hours trading, reflecting the volatility typical of small biotech companies with market caps around $15 million.\n\nQUELIMMUNE, a device-based therapy targeting hyperinflammation in children with acute kidney injury, showed 77% survival at 60 days in clinical trials, compared to a 50% survival rate in historical controls. SeaStar is on track to reach about 25 customers by year-end 2026, with about 20 customers as of the last earnings report. The pediatric market is small, with about 4,000 cases annually in the U.S. and $100 million in annual revenue, while the adult market is vastly larger, with about 200,000 cases annually and $4.5 billion in annual revenue.\n\nThe company is preparing to launch NEUTRALIZE-AKI, an adult trial of the same therapy, with more than 65% enrollment and completion expected by year-end 2026 or early 2027. A CMS billing code for inpatient use is set to take effect on 1 October 2026, potentially enabling faster reimbursement for adult use. SeaStar has received various designations from the FDA and has a Premarket Approval (PMA) filing planned for 2027 for NEUTRALIZE-AKI. The company's main value driver is the NEUTRALIZE-AKI study, a randomized controlled trial of 339 patients, with an expected completion by year-end 2026 or early 2027.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}